(Q44786792)

6 December 2017

title

Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition (English)

1 reference

6 December 2017

1 reference

1 reference

2

1 reference

6 December 2017

3

Kishor M Wasan

1 reference

6 December 2017

1

Leonid Kagan

1 reference

6 December 2017

4

Donald E Mager

1 reference

6 December 2017

publication date

21 June 2013

1 reference

6 December 2017

published in

Pharmaceutical Research

1 reference

6 December 2017

volume

31

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

35-45

1 reference

The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacokinetics and biodistribution of nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacokinetics of amphotericin B in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Is there a correlation between serum antifungal drug concentration and clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Physiological parameter values for physiologically based pharmacokinetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Physiologically Based Pharmacokinetic Modeling: Principles and Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Disposition of amphotericin B in the isolated perfused rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacokinetic and biodistribution studies of Amphotericin B microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Physiologically based pharmacokinetic modeling of nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Allometric scaling of pegylated liposomal anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1127-Z

Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism

21 January 2018

1 reference

12 December 2020

Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential

1 reference

12 December 2020

Non-Michaelis-Menten type hepatic uptake of liposomes in the rat

1 reference

12 December 2020

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

12 December 2020

Amphotericin B lipid preparations: what are the differences?

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats

1 reference

12 December 2020

Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats

1 reference

12 December 2020

Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125

1 reference

12 December 2020

Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling

1 reference

12 December 2020

Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice

1 reference

12 December 2020

Liposome clearance from blood: different animal species have different mechanisms

1 reference

12 December 2020

Pharmacokinetics of amphotericin B in rats as a function of dose following constant‐rate intravenous infusion

1 reference

12 December 2020

Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect.

1 reference

12 December 2020

10.1007/S11095-013-1127-Z

Identifiers

DOI

1 reference

6 December 2017

1 reference